90916-02-2

Upstream product

• 18699-02-0 4-acetamidophenylacetic acid 
• 1197-55-3 4-aminophenylacetic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 104126-70-7 2-(4-amino-3-nitrophenyl)acetic acid ethyl ester 
• 195505-56-7 3-(2,1,3-benzothiadiazol-5-yl)-4-(3,4,5-trimethoxybenzyl)-5-hydroxy-5-(4-methoxyphenyl)-5H-furan-2-one 
• 195505-46-5 ethyl 2-(2,1,3-benzothiadiazol-5-yl)-4-(4-methoxyphenyl)-4-oxobutanoate 
• 195505-47-6 ethyl 2-(2,1,3-benzothiadiazol-5-yl)-acetate 
• 85907-78-4 ethyl 2-(3,4-diaminophenyl)acetate 

Relevant academic research and scientific papers

Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 μM) and in vivo antithrombotic efficacy.

2. ENDOTHELIN antagonists: Evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster

The methylendioxyphenyl group is present in a number of endothelin receptor antagonists thus far reported. By means of a Kohonen neural network we discovered with a benzothiadiazole a bioisosteric replacement instead. This group should be devoid of the negative metabolic interactions with cytochrome P450 ascribed to methylendioxyphenyl in vivo. The synthesis of a potent benzothiadiazole analogue EMD 122801 together with in vitro studies of different methylendioxyphenyl, benzothiadiazole and benzofurazan derivatives is described.